Pregabalin abuse among patients with opioid use disorders may increase the severity of withdrawal symptoms: a single-center, case-control study

References

• Altuner D, Engin N, Gürer C, et al. Substance use and crime: the results of a survey research. Journal of Medical Research. 2009;7(2):87–94.
   Google Scholar
• Uzbay İT, Yüksel N. Substance abuse and addiction. Psikofarmakoloji, modified 3rd edition. Ankara: Çizgi Tıp Yayınevi; 2003; p. 485–520.
   Google Scholar
• Evren C, Ögel K, Uluğ B. Alkol Madde Bağımlılığı Tedavi Kılavuzu [Alcohol substance addiction treatment guide]. 1st ed. Ankara: Türkiye Psikiyatri Derneği Yayınları; 2012; p. 95–101.
   Google Scholar
• Dilbaz N. Madde Bağımlılığı Tanı ve Tedavi Kitapçığı [Substance addiction diagnosis and treatment manual]. Ankara: T.C Sağlık Bakanlığı Tedavi Hizmetleri Genel Müdürlüğü; 2012; p. 63–65.
   Google Scholar
• Shneker BF, McAuley JW. Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacother. 2005;39:2029–2037. doi: 10.1345/aph.1G078
   PubMed Web of Science ®Google Scholar
• Stacey BR, Liss J, Behar R, et al. A systematic review of the effectiveness of policies restricting access to pregabalin. BMC Health Serv Res. 2017;17(1):600. doi: 10.1186/s12913-017-2503-x
   PubMedGoogle Scholar
• Pfizer Inc. Prescribing information: Lyrica. 2013. [cited 2019 Sep 6]. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=561.
   Google Scholar
• Gahr M, Franke B, Freudenmann RW, et al. Concerns about pregabalin: further experience with its potential of causing addictive behaviors. J Addict Med. 2013;7:147–149. doi: 10.1097/ADM.0b013e3182872718
   PubMed Web of Science ®Google Scholar
• Aldemir E, Altıntoprak AE, Coşkunol H. Pregabalin dependence: a case report. Turk Psikiyatri Derg. 2014;25:217–220.
   Web of Science ®Google Scholar
• Grosshans M, Lemenager T, Vollmert C, et al. Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol. 2013;69:2021–2025. doi: 10.1007/s00228-013-1578-5
   PubMed Web of Science ®Google Scholar
• Grosshans M, Mutschler J, Hermann D, et al. Pregabalin abuse, dependence, and withdrawal: a case report. Am J Psychiatry. 2010;167:869–869. doi: 10.1176/appi.ajp.2010.09091269
   PubMed Web of Science ®Google Scholar
• Schwan S, Sundström A, Stjernberg E, et al. A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol. 2010;66:947–953. doi: 10.1007/s00228-010-0853-y
   PubMed Web of Science ®Google Scholar
• Caster O, Edwards IR, Norén GN, et al. Earlier discovery of pregabalin’s dependence potential might have been possible. Eur J Clin Pharmacol. 2011;67:319–320. doi: 10.1007/s00228-010-0920-4
   PubMed Web of Science ®Google Scholar
• Filipetto FA, Zipp CP, Coren JS. Potential for pregabalin abuse or diversion after past drug-seeking behavior. J Am Osteopath Assoc. 2010;110:605–607.
   PubMedGoogle Scholar
• Yargic I, Özdemiroğlu FA. Pregabalin abuse: a case report. Klinik Psikofarmakol Bülteni. 2011;21:64–66. doi: 10.5350/KPB-BCP201121110
   Google Scholar
• Carrus D, Schifano F. Pregabalin misuse-related issues; intake of large dosages, drug-smoking allegations, and possible association with myositis: two case reports. J Clin Psychopharmacol. 2012;32:839–840. doi: 10.1097/JCP.0b013e318272864d
   PubMed Web of Science ®Google Scholar
• Ögel K, Karadağ F, Evren C, et al. Development, validity and reliability study of addiction profile index (BAPI). Turk J Psychiatry. 2012;23(4):264–273.
   Google Scholar
• Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs. 2003;35:253–259. doi: 10.1080/02791072.2003.10400007
   PubMed Web of Science ®Google Scholar
• Altıntoprak AE, Evren C, Aydemir Ö, et al. Reliability and validity study of the Turkish version of the clinical opiate clinical scale. Arch Neuropsychiatr. 2015;52:89–94. doi: 10.5152/npa.2015.7169
   Google Scholar
• Lenhard W, Lenhard A. Calculation of effect sizes. [cited 2019 Sep 6]. Available from: https://www.psychometrica.de/effect_size.html. Dettelbach (Germany): Psychometrica. 2016. doi:10.13140/RG.2.1.3478.4245.
   Google Scholar
• European Medicines Agency (EMA). Lyrica (pregabalin) scientific discussion. Erişim. [cited 2016 Dec 25]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000546/WC500046603.pdf.
   Google Scholar
• Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: placement of pregabalin into schedule V. Final rule. Fed Regist. 2005;70:43633–43635.
   PubMedGoogle Scholar
• Bodén R, Wettermark B, Brandt L, et al. Factors associated with pregabalin dispensing at higher than the approved maximum dose. Eur J Clin Pharmacol. 2014;70(2):197–204. doi: 10.1007/s00228-013-1594-5
   PubMed Web of Science ®Google Scholar
• Lee JD, Friedmann PD, Kinlock TW, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med. 2016;374:1232–1242. doi: 10.1056/NEJMoa1505409
   PubMed Web of Science ®Google Scholar
• Kämmerer N, Lemenager T, Grosshans M, et al. Pregabalin for the reduction of opiate withdrawal symptoms. Psychiatr Prax. 2012;39:351–352. doi: 10.1055/s-0032-1305042
   Web of Science ®Google Scholar
• Krupitsky EM, Ilyuk RD, Mikhailov AD, et al. A randomized single blind study of the efficacy of pregabalin in the treatment of opioid withdrawal syndrome. Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116:29–36. doi: 10.17116/jnevro20161167129-36
   Google Scholar
• Hasanein P, Shakeri S. Pregabalin role in inhibition of morphine analgesic tolerance and physical dependency in rats. Eur J Pharmacol. 2014;742:113–117. doi: 10.1016/j.ejphar.2014.08.030
   PubMed Web of Science ®Google Scholar
• DeFeudis FV. Gamma-aminobutyric acid-ergic analgesia: implications for gamma-aminobutyric acid-ergic therapy for drug addictions. Drug Alcohol Depend. 1984;14:101–111. doi: 10.1016/0376-8716(84)90035-8
   Web of Science ®Google Scholar
• Hull LC, Gabra BH, Bailey CP, et al. Reversal of morphine analgesic tolerance by ethanol in the mouse. J Pharmacol Exp Ther. 2013;345:512–519. doi: 10.1124/jpet.112.202184
   Web of Science ®Google Scholar
• Ma J, Pan ZZ. Contribution of brainstem GABA(A) synaptic transmission to morphine analgesic tolerance. Pain. 2006;122:163–173. doi: 10.1016/j.pain.2006.01.031
   Web of Science ®Google Scholar
• Sivam SP, Ho IK. GABA in morphine analgesia and tolerance. Life Sci. 1985;37:199–208. doi: 10.1016/0024-3205(85)90645-9
   Web of Science ®Google Scholar
• Errante LD, Petroff OAC. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure. 2003;12:300–306. doi: 10.1016/S1059-1311(02)00295-9
   PubMed Web of Science ®Google Scholar
• Asl BH, Hassanzadeh K, Khezri E, et al. Evaluation the effects of dextromethorphan and midazolam on morphine induced tolerance and dependence in mice. Pak J Biol Sci. 2008;11:1690–1695. doi: 10.3923/pjbs.2008.2675.2678
   Google Scholar
• Dobashi T, Tanabe S, Jin H, et al. Valproate attenuates the development of morphine antinociceptive tolerance. Neurosc. Lett. 2010;485:125–128. doi: 10.1016/j.neulet.2010.08.084
   Web of Science ®Google Scholar
• Rahman AF, Takahashi M, Kaneto H. Role of GABAergic systems in the development of morphine tolerance in formalin-treated mice. Jpn J Pharmacol. 1995;68:207–211. doi: 10.1254/jjp.68.207
   Google Scholar
• Yoon I-S, Kim H-S, Hong J-T, et al. Inhibition of muscimol on morphine-induced hyperactivity, reverse tolerance and postsynaptic dopamine receptor supersensitivity. Pharmacology. 2002;65:204–209. doi: 10.1159/000064345
   Web of Science ®Google Scholar
• Pfizer Inc. Prescribing information: Lyrica, 2011. [cited 2016 Dec 25]. Available from: URL: http://www.pfizer.com/products/product-detail/lyrica.
   Google Scholar
• Baldwin DS, Ajel K, Masdrakis VG, et al. Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat. 2013;9:883–892. doi: 10.2147/NDT.S36453
   PubMed Web of Science ®Google Scholar